Chronic Idiopathic Constipation Treatment Market
Chronic Idiopathic Constipation Treatment Market Analysis by Serotonin-4 (5-Ht4) Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, and Stimulants from 2023 to 2033
Analysis of Chronic Idiopathic Constipation Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Chronic Idiopathic Constipation Treatment Market Outlook (2023 to 2033)
The global chronic idiopathic constipation treatment market is set to increase from a valuation of US$ 9.4 billion in 2023 and reach US$ 19.7 billion by the end of 2033, Expanding swiftly at a CAGR of 7.5%.
A common functional bowel condition known as chronic idiopathic constipation (CIC) can be defined when a person experiences difficult, infrequent, and/or unsatisfactory defecation. Sedentary lifestyle, rising use of anti-inflammatory drugs, and a sharp drop in dietary fiber consumption are some of the causes that are increasing the number of people suffering from chronic idiopathic constipation.
- Millions of people worldwide suffer from chronic idiopathic constipation, a very prevalent functional bowel illness. According to the National Center for Biotechnology Information, CIC affects 10% to 17% of the world's population and is more common in women and older people.
Normal-transit constipation and slow-transit constipation are two types of chronic idiopathic constipation. The type of constipation that is typically encountered by the individual is normal-transit constipation. Stool frequency and transit time through the colon are both normal, but patients still report feeling constipated. Patients in this group complain of hard stools, bloating, abdominal pain, or both.
Slow-transit constipation can be identified by decreased large intestine motility, which is brought on by enteric nerve abnormalities. Constipation and excessive soiling are just two examples of the chronic issues brought on by the exceptionally slow-transit of waste through the large intestine.
In the next ten years, the demand for constipation treatment is expected to rise as a result of high R&D spending for the creation of novel drugs for chronic idiopathic constipation, advancements in healthcare facilities, increasing rate of the geriatric population, shifting dietary patterns, and high fast food consumption. Another factor that is projected to fuel the growth of the chronic idiopathic constipation treatment market is the increasing simplicity and accessibility of over-the-counter medications for chronic idiopathic constipation.
Report Attributes |
Details |
|
Market Size (2023E) |
US$ 9.4 Billion |
|
Forecasted Market Value (2033F) |
US$ 19.7 Billion |
|
Global Market Growth Rate (2023 to 2033) |
7.5% CAGR |
|
Leading Regional Market |
North America |
|
Share of Constipation Treatment Market (2023) |
88.2% |
|
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Dynamics are Expected to Drive the Sales of Chronic Idiopathic Constipation Solutions?
“Constant Developments in CIC Treatment Procedures”
Chronic idiopathic constipation was initially treated with a combination of medication review, dietary changes, and patient education. Several non-prescription chronic idiopathic constipation treatments, such as fiber supplementation, have gained popularity, while prescription treatments are anticipated to see widespread use in the coming 10 years.
Evidence suggests that soluble fibers such as psyllium, as opposed to insoluble fibers such as bran, can help people with chronic idiopathic constipation. Because of the notable improvement in overall symptoms and stool consistency that has resulted from the greater intake of soluble fibers, the market for chronic idiopathic constipation treatments is heavily favouring the use of soluble fibers in empiric fiber therapy. Thus, the demand for non-prescription treatments is growing rapidly due to their high adoption rates globally.
“Older Population Mostly Experience Chronic Idiopathic Constipation Problems”
Rising population of geriatric patients is the main factor in the increasing demand for CIC treatment products. The chronic non-cancer pain these patients experience is treated with analgesics such as hydromorphone, codeine, morphine, etc., which have severe side effects on the digestive tract and cause a huge demand for chronic idiopathic constipation medications.
The elderly population over 65 is more vulnerable to chronic illnesses. Constipation-related problems are five times more common in elderly people than in younger adults. Poor food, a lack of adequate fluids in the diet, inactivity, the use of particular medications to treat other medical illnesses, and unfavourable bowel habits are some of the factors leading to constipation in the elderly population.
- According to the World Health Organization Facts of 2021, between the years 2015 to 2050, the percentage of the world's population 60 and older is expected to nearly double, from 12% to 22%.
- By 2030, 1 in every 6 persons on the earth is likely to be of 60 years of age or older.
- By 2050, there are likely to be 1.4 billion people in the world who are 60 years of age and older, up from 1 billion in 2020.
Why Do Patients Prefer Natural Chronic Idiopathic Constipation Treatment Options?
“Preference for Home Remedies Due to High Overall Treatment Costs”
More so than the treatment, patients rely on home remedies. Treatment is connected with medications, dietary, and lifestyle modifications that increase the overall treatment costs. Bowel incontinence carries a heavy social stigma that is linked to mental distress and prevents the disease from being properly diagnosed. Other issues impeding sales of chronic idiopathic constipation drugs are poor reimbursement policies and a lack of knowledge about the treatment of constipation in emerging countries.
- Around 81% expense of treating chronic idiopathic constipation, according to a study issued in the American Journal of Managed Care, is attributed to medical services, such as outpatient care and visits to prescribers.
- According to several studies, persistent constipation patients with abdominal symptoms pay 1.6 times more at the pharmacy than those without those symptoms.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Will New Market Players Be Able to Penetrate the Chronic Idiopathic Constipation Treatment Market?
“Each Patient Has Different Issues – Need to Meet Unique Needs Opens up New Opportunities”
CIC is a chronic condition that requires long-term management, and patients often require different treatment approaches based on the severity of their symptoms. The treatment options for CIC include laxatives, fiber supplements, prokinetics, stool softeners, and other prescription medications. In recent years, there has been a growing demand for newer and more effective treatment options for CIC, as some patients do not respond well to existing therapies or may experience side effects.
The chronic idiopathic constipation treatment market offers several opportunities for new manufacturers to enter. Here are some potential benefits :
- Unmet Needs: Despite the availability of various treatment options, there are still unmet needs in the management of CIC. Some patients do not respond well to existing therapies or may experience side effects, leading to the demand for newer and more effective treatment options. New manufacturers can capitalize on these unmet needs by developing innovative medicines that address these gaps in the market.
- Market Segmentation: The market for chronic idiopathic constipation treatments is diverse, with different patient populations requiring different treatment approaches. For example, elderly patients, pediatric patients, and patients with specific comorbidities may have unique treatment requirements. New manufacturers can focus on specific patient populations and develop tailored treatment options to cater to their needs, thereby creating a major market position for themselves.
- Technological Innovation: Technology has the potential to revolutionize the treatment of CIC. There is a growing interest in developing novel drug delivery systems, such as oral films, nanoparticles, and microspheres, which can enhance the efficacy and safety of chronic idiopathic constipation treatments. New chronic idiopathic constipation drug manufacturers with expertise in advanced drug delivery technologies can bring innovative products with user-friendly designs and disrupt the traditional treatment landscape.
- Patient-centric Approach: Patient-centricity is becoming increasingly important in healthcare, and CIC is no exception. Patients are actively seeking treatments that are convenient, easy to use, and have minimal side effects. New producers of chronic idiopathic constipation solutions can develop patient-centric products that prioritize patient comfort and compliance, such as user-friendly formulations, patient-friendly packaging, and novel administration routes, which can differentiate their products in the market.
Country-wise Analysis
What is the Demand Outlook for Chronic Idiopathic Constipation Treatment Procedures in the United States?
“Presence of Key Market Players and Rising Prevalence of Constipation among All Age Groups”
Rising prevalence of chronic constipation, the presence of key market players, and increasing investments in healthcare are the key factors driving sales of chronic idiopathic constipation treatment solutions.
- Constipation is a common type of illness in Americans of all ages, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Approximately 16 out of every 100 people have constipation in the United States. Therefore, it is anticipated that the demand for chronic idiopathic constipation treatment solutions is likely to rise during the forecast period.
What is Driving the Sales of Chronic Idiopathic Constipation Solutions in Germany?
“Well-established Healthcare & Pharma Facilities”
Germany is one of the countries with advanced healthcare systems in Europe. In recent years, there has been growing interest in novel treatment options for constipation. Advancements in constipation treatment options are expected to drive the growth of the German market for chronic idiopathic constipation treatments.
The prosecretory agents such as lubiprostone and linaclotide, which increase intestinal fluid secretion and promote bowel movement, have shown promising results in clinical trials and are gaining popularity among healthcare professionals. Thus, developments in drug production are expected to generate profitable opportunities for CIC drug manufacturers.
How is Demand for Chronic Idiopathic Constipation Drugs Progressing in Japan?
“High Prevalence of Constipation in Senior Population”
Constipation is a common gastrointestinal disorder that affects millions of people in Japan. One of the key factors driving the constipation treatment market in Japan is the rising prevalence of constipation among the ageing population.
Japan is experiencing demographic shifts with the rising rate of the ageing population. There has been a higher incidence of constipation due to age-related changes in bowel function, medication use, and comorbidities. This is further increasing the demand for effective constipation treatments in the country.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Category-wise Analysis
Which Types of Drugs are Most Popular in This Space?
“Laxatives Considered Most Effective Drugs for Constipation Treatment”
Laxatives are substances that affect the intestines in such a way as to induce bowel movement. When used with or without electrolytes, polyethylene glycol is more effective than a placebo for the treatment of functional constipation. Constipation is treated with methylcellulose fiber, which also helps to maintain regular bowel movements.
Methylcellulose (Citrucel) belongs to the class of laxatives that create large stools. It increases the volume of feces, which improves intestinal motility and controls bowel movements. It is used in conjunction with dietary changes and other therapy to treat constipation and restore and maintain bowel regularity. Thus, the demand for constipation laxatives is increasing rapidly.
Competitive Landscape
According to Fact.MR, a market research and competitive intelligence provider, key players in the chronic idiopathic constipation treatment market are focused on developing technologically advanced solutions, introducing new design products, obtaining regulatory clearances, and partnering and acquiring other businesses.
The FDA approval for newly discovered medications is currently being sought by leading companies in the chronic idiopathic constipation treatment market. Over the forecast period, obtaining FDA approval is anticipated to continue to be one of the primary areas of attention for the producers of medications for chronic idiopathic constipation.
The FDA has just given the all-clear to several medications.
- An osmotic laxative created by Braintree Laboratories (Sebela) was given FDA approval in February 2020 to treat adults with chronic idiopathic constipation.
- Ironwood Pharmaceuticals, Inc. reported in April 2020 that the USPTO has granted certificates of approval for patent applications relating to the formulation of the 72 mcg dose of LINZESS.
- The U.S. Food and Drug Administration granted Sebela Pharmaceuticals, Inc. permission to market Pizensy (lactitol) in March 2020.
Chronic Idiopathic Constipation Treatment Industry Research Segmentation
-
By Type :
- Normal-transit Constipation
- Slow-transit Constipation
-
By Therapy :
- Pharmacological Therapies
- Non-pharmacological Therapies
-
By Treatment :
- Medication
- Surgery
-
By Drug :
- Serotonin-4 (5-Ht4) Receptor Agonist
- Guanylate Cyclase-C Agonist
- Laxatives
- Stimulants
-
By Route of Administration :
- Oral
- Injectable
-
By End User :
- Hospitals
- Homecare
- Specialty Clinics
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Table of Content
1. Executive Summary 1.1. Fact.MR Research Analyzed 1.2. Global Market - Wheel of Fortune (Opportunity Assessment) 1.3. Global Market - Mega Trends 2. Market Introduction 2.1. Global Market Definition 2.2. Research Scope 3. Associated Indicators Assessment 3.1. Market Dynamics 3.1.1. Key Drivers and Trends 3.1.2. Market Challenges 3.2. Value Chain 3.3. Comparison Chart 3.4. Market - Opportunity Analysis 3.5. Market Analysis - Investment Feasibility Index 3.6. Market - PESTLE Analysis 3.7. Market - Porter’s Five Forces Analysis 3.8. Market - Market Positioning Assessment by Regions 3.9. Market Analysis - Forecast Scenario 3.9.1. Market Analysis - Forecast Factors 3.10. Price Point Analysis by Region 3.11. Regulations 3.12. Voice of Customers 3.12.1. Decision Purchase Attributes by Region 3.12.2. Preferred Purchase Points 3.12.3. Market Opportunity by Region 3.13. STP Analysis and Go To Market Strategy (Recommendation) 4. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 4.1. Introduction 4.2. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Type 4.2.1. Normal-transit Constipation 4.2.2. Slow-transit Constipation 4.3. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Therapy 4.3.1. Pharmacological Therapies 4.3.2. Non-pharmacological Therapies 4.4. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Treatment 4.4.1. Medication 4.4.2. Surgery 4.5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Drug 4.5.1. Serotonin-4 (5-Ht4) Receptor Agonist 4.5.2. Guanylate Cyclase-C Agonist 4.5.3. Laxatives 4.5.4. Stimulants 4.6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Route of Administration 4.6.1. Oral 4.6.2. Injectable 4.7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by End User 4.7.1. Hospitals 4.7.2. Homecare 4.7.3. Specialty Clinics 4.8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Region 4.8.1. North America 4.8.2. Latin America 4.8.3. Europe 4.8.4. Japan 4.8.5. APEJ 4.8.6. MEA 5. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 5.1. Introduction 5.2. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country 5.2.1. United States 5.2.2. Canada 5.2.3. Market Value Share and BPS Analysis by Country 5.2.4. Y -o-Y Growth Projections by Country 5.2.5. Absolute $ Opportunity by Country 5.2.6. Market Attractiveness Assessment by Country 5.3. North America Market Value (US$ Mn) and Volume (‘000 Units) by Type 5.3.1. Market Value Share and BPS Analysis by Type 5.3.2. Y-o-Y Growth Projections by Type 5.3.3. Market Attractiveness Assessment by Type 5.4. North America Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 5.4.1. Market Value Share and BPS Analysis by Therapy 5.4.2. Y-o-Y Growth Projections by Therapy 5.4.3. Market Attractiveness Assessment by Therapy 5.5. North America Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 5.5.1. Market Value Share and BPS Analysis by Treatment 5.5.2. Y-o-Y Growth Projections by Treatment 5.5.3. Market Attractiveness Assessment by Treatment 5.6. North America Market Value (US$ Mn) and Volume (‘000 Units) by Drug 5.6.1. Market Value Share and BPS Analysis by Drug 5.6.2. Y-o-Y Growth Projections by Drug 5.6.3. Market Attractiveness Assessment by Drug 5.7. North America Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 5.7.1. Market Value Share and BPS Analysis by Route of Administration 5.7.2. Y-o-Y Growth Projections by Route of Administration 5.7.3. Market Attractiveness Assessment by Route of Administration 5.8. North America Market Value (US$ Mn) and Volume (‘000 Units) by End User 5.8.1. Market Value Share and BPS Analysis by End User 5.8.2. Y-o-Y Growth Projections by End User 5.8.3. Market Attractiveness Assessment by End User 6. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 6.1. Introduction 6.2. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country 6.2.1. Brazil 6.2.2. Mexico 6.2.3. Argentina 6.2.4. Chile 6.2.5. Peru 6.2.6. Rest of Latin America 6.2.7. Market Value Share and BPS Analysis by Country 6.2.8. Y-o-Y Growth Projections by Country 6.2.9. Absolute $ Opportunity by Country 6.2.10. Market Attractiveness Assessment by Country 6.3. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Type 6.3.1. Market Value Share and BPS Analysis by Type 6.3.2. Y-o-Y Growth Projections by Type 6.3.3. Market Attractiveness Assessment by Type 6.4. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 6.4.1. Market Value Share and BPS Analysis by Therapy 6.4.2. Y-o-Y Growth Projections by Therapy 6.4.3. Market Attractiveness Assessment by Therapy 6.5. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 6.5.1. Market Value Share and BPS Analysis by Treatment 6.5.2. Y-o-Y Growth Projections by Treatment 6.5.3. Market Attractiveness Assessment by Treatment 6.6. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Drug 6.6.1. Market Value Share and BPS Analysis by Drug 6.6.2. Y-o-Y Growth Projections by Drug 6.6.3. Market Attractiveness Assessment by Drug 6.7. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 6.7.1. Market Value Share and BPS Analysis by Route of Administration 6.7.2. Y-o-Y Growth Projections by Route of Administration 6.7.3. Market Attractiveness Assessment by Route of Administration 6.8. Latin America Market Value (US$ Mn) and Volume (‘000 Units) by End User 6.8.1. Market Value Share and BPS Analysis by End User 6.8.2. Y-o-Y Growth Projections by End User 6.8.3. Market Attractiveness Assessment by End User 7. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 7.1. Introduction 7.2. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country 7.2.1. EU-4 (Germany, France, Spain, and Italy) 7.2.2. United Kingdom 7.2.3. BENELUX 7.2.4. NORDIC 7.2.5. Rest of Europe 7.2.6. Market Value Share and BPS Analysis by Country 7.2.7. Y-o-Y Growth Projections by Country 7.2.8. Absolute $ Opportunity by Country 7.2.9. Market Attractiveness Assessment by Country 7.3. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Type 7.3.1. Market Value Share and BPS Analysis by Type 7.3.2. Y-o-Y Growth Projections by Type 7.3.3. Market Attractiveness Assessment by Type 7.4. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 7.4.1. Market Value Share and BPS Analysis by Therapy 7.4.2. Y-o-Y Growth Projections by Therapy 7.4.3. Market Attractiveness Assessment by Therapy 7.5. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 7.5.1. Market Value Share and BPS Analysis by Treatment 7.5.2. Y-o-Y Growth Projections by Treatment 7.5.3. Market Attractiveness Assessment by Treatment 7.6. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Drug 7.6.1. Market Value Share and BPS Analysis by Drug 7.6.2. Y-o-Y Growth Projections by Drug 7.6.3. Market Attractiveness Assessment by Drug 7.7. Europe Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 7.7.1. Market Value Share and BPS Analysis by Route of Administration 7.7.2. Y-o-Y Growth Projections by Route of Administration 7.7.3. Market Attractiveness Assessment by Route of Administration 7.8. Europe Market Value (US$ Mn) and Volume (‘000 Units) by End User 7.8.1. Market Value Share and BPS Analysis by End User 7.8.2. Y-o-Y Growth Projections by End User 7.8.3. Market Attractiveness Assessment by End User 8. CIS & Russia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 8.1. Introduction 8.2. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Type 8.2.1. Market Value Share and BPS Analysis by Type 8.2.2. Y-o-Y Growth Projections by Type 8.2.3. Market Attractiveness Assessment by Type 8.3. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 8.3.1. Market Value Share and BPS Analysis by Therapy 8.3.2. Y-o-Y Growth Projections by Therapy 8.3.3. Market Attractiveness Assessment by Therapy 8.4. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 8.4.1. Market Value Share and BPS Analysis by Treatment 8.4.2. Y-o-Y Growth Projections by Treatment 8.4.3. Market Attractiveness Assessment by Treatment 8.5. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Drug 8.5.1. Market Value Share and BPS Analysis by Drug 8.5.2. Y-o-Y Growth Projections by Drug 8.5.3. Market Attractiveness Assessment by Drug 8.6. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 8.6.1. Market Value Share and BPS Analysis by Route of Administration 8.6.2. Y-o-Y Growth Projections by Route of Administration 8.6.3. Market Attractiveness Assessment by Route of Administration 8.7. CIS & Russia Market Value (US$ Mn) and Volume (‘000 Units) by End User 8.7.1. Market Value Share and BPS Analysis by End User 8.7.2. Y-o-Y Growth Projections by End User 8.7.3. Market Attractiveness Assessment by End User 9. Japan Market Analysis 2018 to 2022 and Forecast 2023 to 2033 9.1. Introduction 9.2. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Type 9.2.1. Market Value Share and BPS Analysis by Type 9.2.2. Y-o-Y Growth Projections by Type 9.2.3. Market Attractiveness Assessment by Type 9.3. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 9.3.1. Market Value Share and BPS Analysis by Therapy 9.3.2. Y-o-Y Growth Projections by Therapy 9.3.3. Market Attractiveness Assessment by Therapy 9.4. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 9.4.1. Market Value Share and BPS Analysis by Treatment 9.4.2. Y-o-Y Growth Projections by Treatment 9.4.3. Market Attractiveness Assessment by Treatment 9.5. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Drug 9.5.1. Market Value Share and BPS Analysis by Drug 9.5.2. Y-o-Y Growth Projections by Drug 9.5.3. Market Attractiveness Assessment by Drug 9.6. Japan Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 9.6.1. Market Value Share and BPS Analysis by Route of Administration 9.6.2. Y-o-Y Growth Projections by Route of Administration 9.6.3. Market Attractiveness Assessment by Route of Administration 9.7. Japan Market Value (US$ Mn) and Volume (‘000 Units) by End User 9.7.1. Market Value Share and BPS Analysis by End User 9.7.2. Y-o-Y Growth Projections by End User 9.7.3. Market Attractiveness Assessment by End User 10. APEJ Market Analysis 2018 to 2022 and Forecast 2023 to 2033 10.1. Introduction 10.2. APEJ Market Analysis 2018 to 2022 and Forecast 2023 to 2033 by Country 10.2.1. China 10.2.2. India 10.2.3. Australia & New Zealand 10.2.4. ASEAN 10.2.5. South Korea 10.2.6. Rest of APEJ 10.2.7. Market Value Share and BPS Analysis by Country 10.2.8. Y-o-Y Growth Projections by Country 10.2.9. Absolute $ Opportunity by Country 10.2.10. Market Attractiveness Assessment by Country 10.3. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Type 10.3.1. Market Value Share and BPS Analysis by Type 10.3.2. Y-o-Y Growth Projections by Type 10.3.3. Market Attractiveness Assessment by Type 10.4. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 10.4.1. Market Value Share and BPS Analysis by Therapy 10.4.2. Y-o-Y Growth Projections by Therapy 10.4.3. Market Attractiveness Assessment by Therapy 10.5. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 10.5.1. Market Value Share and BPS Analysis by Treatment 10.5.2. Y-o-Y Growth Projections by Treatment 10.5.3. Market Attractiveness Assessment by Treatment 10.6. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Drug 10.6.1. Market Value Share and BPS Analysis by Drug 10.6.2. Y-o-Y Growth Projections by Drug 10.6.3. Market Attractiveness Assessment by Drug 10.7. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 10.7.1. Market Value Share and BPS Analysis by Route of Administration 10.7.2. Y-o-Y Growth Projections by Route of Administration 10.7.3. Market Attractiveness Assessment by Route of Administration 10.8. APEJ Market Value (US$ Mn) and Volume (‘000 Units) by End User 10.8.1. Market Value Share and BPS Analysis by End User 10.8.2. Y-o-Y Growth Projections by End User 10.8.3. Market Attractiveness Assessment by End User 11. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Country 11.2.1. GCC Countries 11.2.2. South Africa 11.2.3. Turkey 11.2.4. Israel 11.2.5. Rest of MEA 11.2.6. Market Value Share and BPS Analysis by Country 11.2.7. Y-o-Y Growth Projections by Country 11.2.8. Absolute $ Opportunity by Country 11.2.9. Market Attractiveness Assessment by Country 11.3. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Type 11.3.1. Market Value Share and BPS Analysis by Type 11.3.2. Y-o-Y Growth Projections by Type 11.3.3. Market Attractiveness Assessment by Type 11.4. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Therapy 11.4.1. Market Value Share and BPS Analysis by Therapy 11.4.2. Y-o-Y Growth Projections by Therapy 11.4.3. Market Attractiveness Assessment by Therapy 11.5. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Treatment 11.5.1. Market Value Share and BPS Analysis by Treatment 11.5.2. Y-o-Y Growth Projections by Treatment 11.5.3. Market Attractiveness Assessment by Treatment 11.6. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Drug 11.6.1. Market Value Share and BPS Analysis by Drug 11.6.2. Y-o-Y Growth Projections by Drug 11.6.3. Market Attractiveness Assessment by Drug 11.7. MEA Market Value (US$ Mn) and Volume (‘000 Units) by Route of Administration 11.7.1. Market Value Share and BPS Analysis by Route of Administration 11.7.2. Y-o-Y Growth Projections by Route of Administration 11.7.3. Market Attractiveness Assessment by Route of Administration 11.8. MEA Market Value (US$ Mn) and Volume (‘000 Units) by End User 11.8.1. Market Value Share and BPS Analysis by End User 11.8.2. Y-o-Y Growth Projections by End User 11.8.3. Market Attractiveness Assessment by End User 12. Competitive Assessment 12.1. Global Market Structure 12.2. Global Market Competition - a Dashboard View 12.3. Global Market Company Share Analysis 12.4. Market Player Competition Footprint Matrix 12.5. Key Participants Market Presence (Intensity Mapping) by Region 13. Company Profiles 13.1. Bayer AG 13.1.1. Overview 13.1.2. Product Portfolio 13.1.3. Profitability by Market Segments 13.1.4. Sales Footprint 13.2. Allergan 13.2.1. Overview 13.2.2. Product Portfolio 13.2.3. Profitability by Market Segments 13.2.4. Sales Footprint 13.3. Bausch Health 13.3.1. Overview 13.3.2. Product Portfolio 13.3.3. Profitability by Market Segments 13.3.4. Sales Footprint 13.4. Sanofi 13.4.1. Overview 13.4.2. Product Portfolio 13.4.3. Profitability by Market Segments 13.4.4. Sales Footprint 13.5. Takeda Pharmaceutical Company 13.5.1. Overview 13.5.2. Product Portfolio 13.5.3. Profitability by Market Segments 13.5.4. Sales Footprint 13.6. Sebela Pharmaceuticals 13.6.1. Overview 13.6.2. Product Portfolio 13.6.3. Profitability by Market Segments 13.6.4. Sales Footprint 13.7. Ironwood Pharmaceuticals, Inc. 13.7.1. Overview 13.7.2. Product Portfolio 13.7.3. Profitability by Market Segments 13.7.4. Sales Footprint 13.8. Albireo Pharma, Inc. 13.8.1. Overview 13.8.2. Product Portfolio 13.8.3. Profitability by Market Segments 13.8.4. Sales Footprint 13.9. Sucampo Pharmaceuticals, Inc. (Mallinckrodt) 13.9.1. Overview 13.9.2. Product Portfolio 13.9.3. Profitability by Market Segments 13.9.4. Sales Footprint 13.10. Janssen Pharmaceuticals, Inc. 13.10.1. Overview 13.10.2. Product Portfolio 13.10.3. Profitability by Market Segments 13.10.4. Sales Footprint 13.11. Synergy Pharmaceuticals Inc. 13.11.1. Overview 13.11.2. Product Portfolio 13.11.3. Profitability by Market Segments 13.11.4. Sales Footprint 13.12. Shandong Luoxin Pharmaceutical Group Stock Co., Ltd 13.12.1. Overview 13.12.2. Product Portfolio 13.12.3. Profitability by Market Segments 13.12.4. Sales Footprint 13.13. Zydus Cadila 13.13.1. Overview 13.13.2. Product Portfolio 13.13.3. Profitability by Market Segments 13.13.4. Sales Footprint 13.14. Boehringer Ingelheim International GmbH 13.14.1. Overview 13.14.2. Product Portfolio 13.14.3. Profitability by Market Segments 13.14.4. Sales Footprint 13.15. Abbott Laboratories 13.15.1. Overview 13.15.2. Product Portfolio 13.15.3. Profitability by Market Segments 13.15.4. Sales Footprint 13.16. GlaxoSmithKline Plc 13.16.1. Overview 13.16.2. Product Portfolio 13.16.3. Profitability by Market Segments 13.16.4. Sales Footprint 13.17. Troikaa Pharmaceuticals Ltd 13.17.1. Overview 13.17.2. Product Portfolio 13.17.3. Profitability by Market Segments 13.17.4. Sales Footprint 13.18. Lupin 13.18.1. Overview 13.18.2. Product Portfolio 13.18.3. Profitability by Market Segments 13.18.4. Sales Footprint 13.19. East West Pharma 13.19.1. Overview 13.19.2. Product Portfolio 13.19.3. Profitability by Market Segments 13.19.4. Sales Footprint 13.20. Ferring B.V. 13.20.1. Overview 13.20.2. Product Portfolio 13.20.3. Profitability by Market Segments 13.20.4. Sales Footprint 13.21. Albireo Pharma, Inc. 13.21.1. Overview 13.21.2. Product Portfolio 13.21.3. Profitability by Market Segments 13.21.4. Sales Footprint 14. Assumptions and Acronyms Used 15. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
TABLE 01: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 02: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 03: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 04: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 05: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 06: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 07: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 08: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 09: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 10: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 11: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 12: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 13: Global Value (US$ Mn) and Volume (‘000 Units) Analysis, By Region, 2018 to 2033
TABLE 14: Global Value (US$ Mn) and Volume (‘000 Units) Forecast, By Region, 2022 - 2032
TABLE 15: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Country, 2018 to 2033
TABLE 16: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Country, 2022 - 2032
TABLE 17: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 18: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 19: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 20: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 21: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 22: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 23: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 24: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 25: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 26: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 27: North America Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 28: North America Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 29: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Country, 2018 to 2033
TABLE 30: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Country, 2022 - 2032
TABLE 31: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 32: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 33: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 34: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 35: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 36: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 37: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 38: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 39: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 40: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 41: Latin America Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 42: Latin America Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 43: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By Country, 2018 to 2033
TABLE 44: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By Country, 2022 - 2032
TABLE 45: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 46: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 47: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 48: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 49: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 50: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 51: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 52: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 53: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 54: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 55: Europe Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 56: Europe Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 57: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 58: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 59: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 60: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 61: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 62: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 63: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 64: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 65: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 66: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 67: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 68: CIS & Russia Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 69: Japan Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 70: Japan Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 71: Japan Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 72: Japan Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 73: Japan Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 74: Japan Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 75: Japan Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 76: Japan Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 77: Japan Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 78: Japan Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 79: Japan Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 80: Japan Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 81: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By Country, 2018 to 2033
TABLE 82: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By Country, 2022 - 2032
TABLE 83: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 84: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 85: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 86: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 87: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 88: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 89: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 90: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 91: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 92: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 93: APEJ Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 94: APEJ Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
TABLE 95: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By Country, 2018 to 2033
TABLE 96: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By Country, 2022 - 2032
TABLE 97: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By Type, 2018 to 2033
TABLE 98: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By Type, 2022 - 2032
TABLE 99: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By Therapy, 2018 to 2033
TABLE 100: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By Therapy, 2022 - 2032
TABLE 101: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By Treatment, 2018 to 2033
TABLE 102: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By Treatment, 2022 - 2032
TABLE 103: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By Drug, 2018 to 2033
TABLE 104: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By Drug, 2022 - 2032
TABLE 105: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By Route of Administration, 2018 to 2033
TABLE 106: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By Route of Administration, 2022 - 2032
TABLE 107: MEA Value (US$ Mn) and Volume (‘000 Units) Analysis, By End User, 2018 to 2033
TABLE 108: MEA Value (US$ Mn) and Volume (‘000 Units) Forecast, By End User, 2022 - 2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIGURE 01: Global Market Value (US$ Mn), 2018 to 2033
FIGURE 02: Global Market Volume (‘000 Units), 2018 to 2033
FIGURE 03: Global Historic Market Size and Volume, 2018 to 2022
FIGURE 04: Global Forecast Market Size and Volume, 2023 to 2033
FIGURE 05: Global Market Value Forecast (US$ Mn) & Y-o-Y Growth, 2018 to 2033
FIGURE 06: Global Market Absolute $ Opportunity, 2018 to 2033
FIGURE 07: Global Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 08: Global Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 09: Global Standard Market Opportunity Index, 2018 to 2033
FIGURE 10: Global Wireless Market Opportunity Index, 2018 to 2033
FIGURE 11: Global Market Attractiveness Index by Type, 2023 to 2033
FIGURE 12: Global Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 13: Global Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 14: Global < 8 MP Market Opportunity Index, 2018 to 2033
FIGURE 15: Global 8 to 12 MP Market Opportunity Index, 2018 to 2033
FIGURE 16: Global > 12 MP Market Opportunity Index, 2018 to 2033
FIGURE 17: Global Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 18: Global Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 19: Global Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 20: Global White Flash Market Opportunity Index, 2018 to 2033
FIGURE 21: Global Low Glow Market Opportunity Index, 2018 to 2033
FIGURE 22: Global No Glow Market Opportunity Index, 2018 to 2033
FIGURE 23: Global Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 24: Global Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 25: Global Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 26: Global Up to 0.25 Sec Market Opportunity Index, 2018 to 2033
FIGURE 27: Global 0.25 Sec to 0.75 Sec Market Opportunity Index, 2018 to 2033
FIGURE 28: Global Above 0.75 Sec Market Opportunity Index, 2018 to 2033
FIGURE 29: Global Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 30: Global Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 31: Global Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 32: Global Hunting Segment Opportunity Index, 2018 to 2033
FIGURE 33: Global Wildlife Monitoring Segment Opportunity Index, 2018 to 2033
FIGURE 34: Global Others (Residential, Utility, Commercial) Market Opportunity Index, 2018 to 2033
FIGURE 35: Global Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 36: Global Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 37: Global Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 38: Global Modern Trade Channels Segment Opportunity Index, 2018 to 2033
FIGURE 39: Global Independent/Brick and Mortar Outlets Segment Opportunity Index, 2018 to 2033
FIGURE 40: Global Direct to Customer Segment Opportunity Index, 2018 to 2033
FIGURE 41: Global Third Party Online Channel Segment Opportunity Index, 2018 to 2033
FIGURE 42: Global Market Attractiveness Index by End User, 2023 to 2033
FIGURE 43: Global Market Share and BPS Analysis by Region- 2018, 2023 & 2033
FIGURE 44: Global Market Y-o-Y Growth Projections by Region, 2018 to 2033
FIGURE 45: North America Market Opportunity Index, 2018 to 2033
FIGURE 46: Latin America Market Opportunity Index, 2018 to 2033
FIGURE 47: Europe Market Opportunity Index, 2018 to 2033
FIGURE 48: CIS & Russia Market Opportunity Index, 2018 to 2033
FIGURE 49: Japan Market Opportunity Index, 2018 to 2033
FIGURE 50: APEJ Market Opportunity Index, 2018 to 2033
FIGURE 51: MEA Market Opportunity Index, 2018 to 2033
FIGURE 52: Global Market Attractiveness Index by Region, 2023 to 2033
FIGURE 53: North America Market Value (US$ Mn), 2018 to 2033
FIGURE 54: North America Market Volume (‘000 Units), 2018 to 2033
FIGURE 55: North America Historic Market Size and Volume, 2018 to 2022
FIGURE 56: North America Forecast Market Size and Volume, 2023 to 2033
FIGURE 57: North America Market Share and BPS Analysis by Country- 2018, 2023 & 2033
FIGURE 58: North America Market Y-o-Y Growth Projections by Country, 2018 to 2033
FIGURE 59: US Market Opportunity Index, 2018 to 2033
FIGURE 60: Canada Market Opportunity Index, 2018 to 2033
FIGURE 61: North America Market Attractiveness Index by Country, 2023 to 2033
FIGURE 62: North America Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 63: North America Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 64: North America Market Attractiveness Index by Type, 2023 to 2033
FIGURE 65: North America Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 66: North America Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 67: North America Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 68: North America Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 69: North America Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 70: North America Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 71: North America Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 72: North America Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 73: North America Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 74: North America Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 75: North America Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 76: North America Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 77: North America Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 78: North America Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 79: North America Market Attractiveness Index by End User, 2023 to 2033
FIGURE 80: Latin America Market Value (US$ Mn), 2018 to 2033
FIGURE 81: Latin America Market Volume (‘000 Units), 2018 to 2033
FIGURE 82: Latin America Historic Market Size and Volume, 2018 to 2022
FIGURE 83: Latin America Forecast Market Size and Volume, 2023 to 2033
FIGURE 84: Latin America Market Share and BPS Analysis by Country- 2018, 2023 & 2033
FIGURE 85: Latin America Market Y-o-Y Growth Projections by Country, 2018 to 2033
FIGURE 86: Brazil Market Opportunity Index, 2018 to 2033
FIGURE 87: Mexico Market Opportunity Index, 2018 to 2033
FIGURE 88: Argentina Market Opportunity Index, 2018 to 2033
FIGURE 89: Chile Market Opportunity Index, 2018 to 2033
FIGURE 90: Peru Market Opportunity Index, 2018 to 2033
FIGURE 91: Rest of Latin America Market Opportunity Index, 2018 to 2033
FIGURE 92: Latin America Market Attractiveness Index by Country, 2023 to 2033
FIGURE 93: Latin America Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 94: Latin America Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 95: Latin America Market Attractiveness Index by Type, 2023 to 2033
FIGURE 96: Latin America Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 97: Latin America Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 98: Latin America Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 99: Latin America Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 100: Latin America Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 101: Latin America Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 102: Latin America Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 103: Latin America Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 104: Latin America Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 105: Latin America Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 106: Latin America Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 107: Latin America Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 108: Latin America Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 109: Latin America Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 110: Latin America Market Attractiveness Index by End User, 2023 to 2033
FIGURE 111: Europe Market Value (US$ Mn), 2018 to 2033
FIGURE 112: Europe Market Volume (‘000 Units), 2018 to 2033
FIGURE 113: Europe Historic Market Size and Volume, 2018 to 2022
FIGURE 114: Europe Forecast Market Size and Volume, 2023 to 2033
FIGURE 115: Europe Market Share and BPS Analysis by Country- 2018, 2023 & 2033
FIGURE 116: Europe Market Y-o-Y Growth Projections by Country, 2018 to 2033
FIGURE 117: EU-4 Market Opportunity Index, 2018 to 2033
FIGURE 118: UK Market Opportunity Index, 2018 to 2033
FIGURE 119: BENELUX Market Opportunity Index, 2018 to 2033
FIGURE 120: NORDIC Market Opportunity Index, 2018 to 2033
FIGURE 121: Rest of Europe Market Opportunity Index, 2018 to 2033
FIGURE 122: Europe Market Attractiveness Index by Country, 2023 to 2033
FIGURE 123: Europe Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 124: Europe Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 125: Europe Market Attractiveness Index by Type, 2023 to 2033
FIGURE 126: Europe Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 127: Europe Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 128: Europe Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 129: Europe Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 130: Europe Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 131: Europe Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 132: Europe Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 133: Europe Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 134: Europe Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 135: Europe Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 136: Europe Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 137: Europe Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 138: Europe Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 139: Europe Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 140: Europe Market Attractiveness Index by End User, 2023 to 2033
FIGURE 141: CIS & Russia Market Value (US$ Mn), 2018 to 2033
FIGURE 142: CIS & Russia Market Volume (‘000 Units), 2018 to 2033
FIGURE 143: CIS & Russia Historic Market Size and Volume, 2018 to 2022
FIGURE 144: CIS & Russia Forecast Market Size and Volume, 2023 to 2033
FIGURE 145: CIS & Russia Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 146: CIS & Russia Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 147: CIS & Russia Market Attractiveness Index by Type, 2023 to 2033
FIGURE 148: CIS & Russia Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 149: CIS & Russia Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 150: CIS & Russia Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 151: CIS & Russia Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 152: CIS & Russia Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 153: CIS & Russia Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 154: CIS & Russia Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 155: CIS & Russia Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 156: CIS & Russia Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 157: CIS & Russia Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 158: CIS & Russia Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 159: CIS & Russia Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 160: CIS & Russia Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 161: CIS & Russia Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 162: CIS & Russia Market Attractiveness Index by End User, 2023 to 2033
FIGURE 163: Japan Market Value (US$ Mn), 2018 to 2033
FIGURE 164: Japan Market Volume (‘000 Units), 2018 to 2033
FIGURE 165: Japan Historic Market Size and Volume, 2018 to 2022
FIGURE 166: Japan Forecast Market Size and Volume, 2023 to 2033
FIGURE 167: Japan Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 168: Japan Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 169: Japan Market Attractiveness Index by Type, 2023 to 2033
FIGURE 170: Japan Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 171: Japan Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 172: Japan Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 173: 0Japan Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 174: Japan Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 175: Japan Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 176: Japan Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 177: Japan Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 178: Japan Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 179: Japan Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 180: Japan Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 181: Japan Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 182: Japan Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 183: Japan Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 184: Japan Market Attractiveness Index by End User, 2023 to 2033
FIGURE 185: APEJ Market Value (US$ Mn), 2018 to 2033
FIGURE 186: APEJ Market Volume (‘000 Units), 2018 to 2033
FIGURE 187: APEJ Historic Market Size and Volume, 2018 to 2022
FIGURE 188: APEJ Forecast Market Size and Volume, 2023 to 2033
FIGURE 189: APEJ Market Share and BPS Analysis by Country- 2018, 2023 & 2033
FIGURE 190: APEJ Market Y-o-Y Growth Projections by Country, 2018 to 2033
FIGURE 191: China Market Opportunity Index, 2018 to 2033
FIGURE 192: India Market Opportunity Index, 2018 to 2033
FIGURE 193: Australia & New Zealand Market Opportunity Index, 2018 to 2033
FIGURE 194: ASEAN Market Opportunity Index, 2018 to 2033
FIGURE 195: South Korea Market Opportunity Index, 2018 to 2033
FIGURE 196: Rest of APEJ Market Opportunity Index, 2018 to 2033
FIGURE 197: APEJ Market Attractiveness Index by Country, 2023 to 2033
FIGURE 198: APEJ Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 199: APEJ Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 200: APEJ Market Attractiveness Index by Type, 2023 to 2033
FIGURE 201: APEJ Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 202: APEJ Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 203: APEJ Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 204: APEJ Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 205: APEJ Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 206: APEJ Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 207: APEJ Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 208: APEJ Market Attractiveness Index by Drug, 2023 to 2033
FIGURE 209: APEJ Market Share and BPS Analysis by Route of Administration- 2018, 2023 & 2033
FIGURE 210: APEJ Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 211: APEJ Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 212: APEJ Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 213: APEJ Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2033
FIGURE 214: APEJ Market Attractiveness Index by Route of Administration, 2023 to 2033
FIGURE 215: APEJ Market Share and BPS Analysis by End User- 2018, 2023 & 2033
FIGURE 216: APEJ Market Y-o-Y Growth Projections by End User, 2018 to 2033
FIGURE 217: APEJ Market Attractiveness Index by End User, 2023 to 2033
FIGURE 218: MEA Market Value (US$ Mn), 2018 to 2033
FIGURE 219: MEA Market Volume (‘000 Units), 2018 to 2033
FIGURE 220: MEA Historic Market Size and Volume, 2018 to 2022
FIGURE 221: MEA Forecast Market Size and Volume, 2023 to 2033
FIGURE 222: MEA Market Share and BPS Analysis by Country- 2018, 2023 & 2033
FIGURE 223: MEA Market Y-o-Y Growth Projections by Country, 2018 to 2033
FIGURE 224: GCC Countries Market Opportunity Index, 2018 to 2033
FIGURE 225: South Africa Market Opportunity Index, 2018 to 2033
FIGURE 226: Turkey Market Opportunity Index, 2018 to 2033
FIGURE 227: Israel Market Opportunity Index, 2018 to 2033
FIGURE 228: Rest of MEA Market Opportunity Index, 2018 to 2033
FIGURE 229: MEA Market Attractiveness Index by Country, 2023 to 2033
FIGURE 230: MEA Market Share and BPS Analysis by Type- 2018, 2023 & 2033
FIGURE 231: MEA Market Y-o-Y Growth Projections by Type, 2018 to 2033
FIGURE 232: MEA Market Attractiveness Index by Type, 2023 to 2033
FIGURE 233: MEA Market Share and BPS Analysis by Therapy- 2018, 2023 & 2033
FIGURE 234: MEA Market Y-o-Y Growth Projections by Therapy, 2018 to 2033
FIGURE 235: MEA Market Attractiveness Index by Therapy, 2023 to 2033
FIGURE 236: MEA Market Share and BPS Analysis by Treatment- 2018, 2023 & 2033
FIGURE 237: MEA Market Y-o-Y Growth Projections by Treatment, 2018 to 2033
FIGURE 238: MEA Market Attractiveness Index by Treatment, 2023 to 2033
FIGURE 239: MEA Market Share and BPS Analysis by Drug- 2018, 2023 & 2033
FIGURE 240: MEA Market Y-o-Y Growth Projections by Drug, 2018 to 2033
FIGURE 241: MEA Market Attractiveness Index by Drug, 2023 to 2033
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the chronic idiopathic constipation treatment market value in 2023?
The global chronic idiopathic constipation treatment market is valued at US$ 9.4 billion in 2023.
What is the estimated CAGR for the chronic idiopathic constipation treatment market?
Global sales of chronic idiopathic constipation treatment solutions are set to increase at a CAGR of 7.5% from 2023 to 2033.
What is the projected market value for chronic idiopathic constipation treatment by 2033?
Demand for chronic idiopathic constipation treatment solutions is expected to reach US$ 19.7 billion by 2033.
Who are the leading providers of chronic idiopathic constipation drugs?
Ironwood Pharmaceuticals, Inc., Sebela Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH are some of the leading companies in the market.
Which is the most profitable regional market for chronic idiopathic constipation treatment?
North America currently accounts for a leading position in the global market.
Chronic Idiopathic Constipation Treatment Market